Key Takeaways
- • Fathom Therapeutics, formerly Atommap Corp. and headquartered in New York City, received an investment from Kos Biotechnology Partners as part of a Series A financing led by Sutter Hill Ventures.
- • The company uses quantum chemistry and AI to design novel drug molecules, with its Microcosmos platform simulating protein dynamics to support small-molecule design with reduced off-target risk.
- • Fathom plans to use the proceeds to scale its platform, advance its internal pipeline, and expand strategic partnerships.
- • The company has an active internal pipeline, multiple discovery partnerships, and a lead program that has advanced into animal efficacy studies.
Summary
Fathom Therapeutics, previously known as Atommap Corp., has received an investment from Kos Biotechnology Partners as part of a Series A financing round led by Sutter Hill Ventures, according to FinSMEs. The New York City-based company applies quantum chemistry and artificial intelligence to drug discovery, designing novel drug molecules through physics-based simulations.
The company is led by CEO Huafeng Xu. Its core technology, the Microcosmos platform, simulates protein motion and interactions at atomic resolution. According to the report, this produces the data needed to design small molecules with differentiated therapeutic effects and reduced off-target risk.
Fathom intends to deploy the new capital to scale its platform, advance its internal pipeline, and expand its strategic partnerships. The company currently maintains an active internal pipeline and multiple discovery partnerships, and its lead program has progressed into animal efficacy studies. The company also has a second office in Boston.
The article does not disclose the size of the Series A round or the individual contribution from Kos Biotechnology Partners.
The company is led by CEO Huafeng Xu. Its core technology, the Microcosmos platform, simulates protein motion and interactions at atomic resolution. According to the report, this produces the data needed to design small molecules with differentiated therapeutic effects and reduced off-target risk.
Fathom intends to deploy the new capital to scale its platform, advance its internal pipeline, and expand its strategic partnerships. The company currently maintains an active internal pipeline and multiple discovery partnerships, and its lead program has progressed into animal efficacy studies. The company also has a second office in Boston.
The article does not disclose the size of the Series A round or the individual contribution from Kos Biotechnology Partners.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.